This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (125)  • Contact me when this article is cited  Related Content  • Related letters  • Similar articles in JAMA  Topic Collections  • Endocrine Diseases, Other  • Alert me on articles by topic

Kenneth Maiese, MD; Faqi Li, MD, PhD; Zhao Zhong Chong, MD, PhD

JAMA. 2005;293:90-95.

Discovery that the hormone erythropoietin (EPO) and its receptor play a significant biological role in tissues outside of the hematopoietic system has fueled significant interest in EPO as a novel cytoprotective agent in both neuronal and vascular systems. Erythropoietin is now considered to have applicability in a variety of disorders that include cerebral ischemia, myocardial infarction, and chronic congestive heart failure. Erythropoietin modulates a broad array of cellular processes that include progenitor stem cell development, cellular integrity, and angiogenesis. As a result, cellular protection by EPO is robust and EPO inhibits the apoptotic mechanisms of injury, including the preservation of cellular membrane asymmetry to prevent inflammation. As the investigation into clinical applications for EPO that maximize efficacy and minimize toxicity progresses, a deeper appreciation for the novel roles that EPO plays in the brain and heart and throughout the entire body should be acquired.

Author Affiliations: Division of Cellular and Molecular Cerebral Ischemia (Drs Maiese, Li, and Chong); Departments of Neurology and Anatomy & Cell Biology, Center for Molecular Medicine and Genetics, Institute of Environmental Health Sciences (Dr Maiese), Wayne State University School of Medicine, Detroit, Mich.

RELATED LETTERS

Erythropoietin and Cancer
Leonard Sadoff
JAMA. 2005;293(15):1858.
EXTRACT | FULL TEXT  

Erythropoietin and Cancer—Reply
Kenneth Maiese, Faqi Li, and Zhao Zhong Chong
JAMA. 2005;293(15):1858-1859.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

A Phase I, Single and Fractionated, Ascending-Dose Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of an Erythropoietin Mimetic Antibody Fusion Protein (CNTO 528) in Healthy Male Subjects
Bouman-Thio et al.
J Clin Pharmacol 2008;48:1197-1207.
ABSTRACT | FULL TEXT  

EPO induces rise in serum ADMA but does not prevent the increase in NO release: the likely involvement of HO-1
Calo and Davis
Nephrol Dial Transplant 2008;23:3035-3036.
FULL TEXT  

Erythropoietin in cardioprotection: does it have a future or is it all in the past?
Mehta
Cardiovasc Res 2008;79:549-550.
FULL TEXT  

An Approach to Using Recombinant Erythropoietin for Neuroprotection in Very Preterm Infants
Fauchere et al.
Pediatrics 2008;122:375-382.
ABSTRACT | FULL TEXT  

Erythropoietin enhancement of rat pancreatic tumor cell proliferation requires the activation of ERK and JNK signals
Bose and Udupa
Am. J. Physiol. Cell Physiol. 2008;295:C394-C405.
ABSTRACT | FULL TEXT  

EPO receptor circuits for primary erythroblast survival
Sathyanarayana et al.
Blood 2008;111:5390-5399.
ABSTRACT | FULL TEXT  

Human recombinant erythropoietin augments serum asymmetric dimethylarginine concentrations but does not compromise nitric oxide generation in mice
Desai et al.
Nephrol Dial Transplant 2008;23:1513-1520.
ABSTRACT | FULL TEXT  

Asialoerythropoietin Prevents Contrast-Induced Nephropathy
Yokomaku et al.
J. Am. Soc. Nephrol. 2008;19:321-328.
ABSTRACT | FULL TEXT  

Cellular Protection by Erythropoietin: New Therapeutic Implications?
Joyeux-Faure
J. Pharmacol. Exp. Ther. 2007;323:759-762.
ABSTRACT | FULL TEXT  

EPO modulation of cell-cycle regulatory genes, and cell division, in primary bone marrow erythroblasts
Fang et al.
Blood 2007;110:2361-2370.
ABSTRACT | FULL TEXT  

Erythropoietin use in critically ill patients: forest and trees
Corwin
CMAJ 2007;177:747-749.
FULL TEXT  

Efficacy and Safety of Epoetin Alfa in Critically Ill Patients
Corwin et al.
NEJM 2007;357:965-976.
ABSTRACT | FULL TEXT  

An extracellular region of the erythropoietin receptor of the subterranean blind mole rat Spalax enhances receptor maturation
Ravid et al.
Proc. Natl. Acad. Sci. USA 2007;104:14360-14365.
ABSTRACT | FULL TEXT  

Erythropoietin Induces Excessive Neointima Formation: A Study in a Rat Carotid Artery Model of Vascular Injury
Reddy et al.
J CARDIOVASC PHARMACOL THER 2007;12:237-247.
ABSTRACT  

Enhanced susceptibility to suicidal death of erythrocytes from transgenic mice overexpressing erythropoietin
Foller et al.
Am. J. Physiol. Regul. Integr. Comp. Physiol. 2007;293:R1127-R1134.
ABSTRACT | FULL TEXT  

Erythropoietin improves cardiac function through endothelial progenitor cell and vascular endothelial growth factor mediated neovascularization
Westenbrink et al.
Eur Heart J 2007;28:2018-2027.
ABSTRACT | FULL TEXT  

Early haemoglobin-independent increase of plasma erythropoietin levels in patients with acute myocardial infarction
Ferrario et al.
Eur Heart J 2007;28:1805-1813.
ABSTRACT | FULL TEXT  

Erythropoietin modulation of podocalyxin and a proposed erythroblast niche
Sathyanarayana et al.
Blood 2007;110:509-518.
ABSTRACT | FULL TEXT  

Can erythropoietin improve skeletal myoblast engraftment in infarcted myocardium?
Chanseaume et al.
ICVTS 2007;6:293-297.
ABSTRACT | FULL TEXT  

Protective Role of Endogenous Erythropoietin System in Nonhematopoietic Cells Against Pressure Overload-Induced Left Ventricular Dysfunction in Mice
Asaumi et al.
Circulation 2007;115:2022-2032.
ABSTRACT | FULL TEXT  

Erythropoietin and the cardiorenal syndrome: cellular mechanisms on the cardiorenal connectors
Jie et al.
Am. J. Physiol. Renal Physiol. 2006;291:F932-F944.
ABSTRACT | FULL TEXT  

Understanding the Presence and Function of Erythropoietin Receptors on Cancer Cells
Lai and Grandis
JCO 2006;24:4675-4676.
FULL TEXT  

Erythropoietin improves myocardial performance in doxorubicin-induced cardiomyopathy
Hamed et al.
Eur Heart J 2006;27:1876-1883.
ABSTRACT | FULL TEXT  

In vivo stimulatory effect of erythropoietin on endothelial nitric oxide synthase in cerebral arteries
Santhanam et al.
Am. J. Physiol. Heart Circ. Physiol. 2006;291:H781-H786.
ABSTRACT | FULL TEXT  

Erythropoietin affords additional cardioprotection to preconditioned hearts by enhanced phosphorylation of glycogen synthase kinase-3beta
Nishihara et al.
Am. J. Physiol. Heart Circ. Physiol. 2006;291:H748-H755.
ABSTRACT | FULL TEXT  

Pretreatment with recombined human erythropoietin attenuates ischemia-reperfusion-induced lung injury in rats.
Wu et al.
Eur. J. Cardiothorac. Surg. 2006;29:902-907.
ABSTRACT | FULL TEXT  

Erythropoietin Delivery by Genetically Engineered Bone Marrow Stromal Cells for Correction of Anemia in Mice with Chronic Renal Failure
Eliopoulos et al.
J. Am. Soc. Nephrol. 2006;17:1576-1584.
ABSTRACT | FULL TEXT  

Epoetin Alfa and Darbepoetin Alfa Go Head to Head
Steensma and Loprinzi
JCO 2006;24:2233-2236.
FULL TEXT  

Alteration in Erythropoietin-Induced Cardioprotective Signaling by Postinfarct Ventricular Remodeling
Miki et al.
J. Pharmacol. Exp. Ther. 2006;317:68-75.
ABSTRACT | FULL TEXT  

Angiogenesis and Endothelial Cell Repair in Renal Disease and Allograft Rejection
Reinders et al.
J. Am. Soc. Nephrol. 2006;17:932-942.
ABSTRACT | FULL TEXT  

Recent Advances in Neonatal Pharmacotherapy
Calhoun et al.
The Annals of Pharmacotherapy 2006;40:710-719.
ABSTRACT | FULL TEXT  

Toward a Multimodal Neuroprotective Treatment of Stroke
Fisher et al.
Stroke 2006;37:1129-1136.
ABSTRACT | FULL TEXT  

Core erythropoietin receptor signals for late erythroblast development
Menon et al.
Blood 2006;107:2662-2672.
ABSTRACT | FULL TEXT  

Important Role of Endogenous Erythropoietin System in Recruitment of Endothelial Progenitor Cells in Hypoxia-Induced Pulmonary Hypertension in Mice
Satoh et al.
Circulation 2006;113:1442-1450.
ABSTRACT | FULL TEXT  

Erythropoietin, Modified to Not Stimulate Red Blood Cell Production, Retains Its Cardioprotective Properties
Moon et al.
J. Pharmacol. Exp. Ther. 2006;316:999-1005.
ABSTRACT | FULL TEXT  

Erythropoietin inhibits apoptosis in breast cancer cells via an Akt-dependent pathway without modulating in vivo chemosensitivity.
Hardee et al.
Molecular Cancer Therapeutics 2006;5:356-361.
ABSTRACT | FULL TEXT  

Erythropoietin Biology in Cancer
Hardee et al.
Clin. Cancer Res. 2006;12:332-339.
ABSTRACT | FULL TEXT  

Erythropoietin Use in Cancer Patients: A Matter of Life and Death?
Steensma and Loprinzi
JCO 2005;23:5865-5868.
FULL TEXT  

Don't Give Up on Erythropoietin as a Neuroprotective Agent
Dame and Fahnenstich
Pediatrics 2005;116:521-522.
FULL TEXT  

Erythropoietin and Cancer
Sadoff
JAMA 2005;293:1858-1858.
FULL TEXT